Identifying remyelinating agents for drug discovery
Multiple Sclerosis is a debilitating neurodegenerative disease that is characterised by lost of myelin in the central nervous system. This results in progressive neurodegeneration and increased clinical disability scores in patients. Despite being on treatments that targets the peripheral immune system, patients continue to progress, arguably due to the accumulation of denuded axons and thus neurodegeneration. Our goal is to halt or slow down the progression of the disease by promoting remyelination through the stimulation of oligodendrocyte precursor cell differentiation. I will describe how we use basic science and a combination of in vitro and ex vivo techniques to identify new targets for remyelination as well as describe how we have adapted these well-worn assays used in academia in a pharma setting.